Drugs.com New Drug ApplicationsOriginal article
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
NDA FilingOxylanthanum CarbonatePositive
AI Analysis
Summary
Unicycive Therapeutics announced the resubmission of a New Drug Application for oxylanthanum carbonate, a therapy for kidney disease patients.
Outcome Details
Resubmission of New Drug Application
Importance:6/10
Sentiment:
0.50
regulatoryNDA resubmissionkidney diseaseUnicycive
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on September 29, 2026 4:09 AM